GSA Capital Partners LLP Grows Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
GSA Capital Partners LLP Grows Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
GSA Capital Partners LLP boosted its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) by 186.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 117,109 shares of the company's stock after buying an additional 76,224 shares during the period. GSA Capital Partners LLP owned approximately 0.29% of Taysha Gene Therapies worth $764,000 at the end of the most recent quarter.
GSA Capital Partners LLP最近向美國證券交易委員會提交的13F文件顯示，該公司在第一季度增持了泰莎基因療法公司(TSHA-GET Rating)的股份186.4%。該公司持有117,109股該公司股票，在此期間又購買了76,224股。截至最近一個季度末，GSA Capital Partners LLP擁有塔莎基因療法公司約0.29%的股份，價值76.4萬美元。
Several other hedge funds and other institutional investors also recently bought and sold shares of TSHA. ProShare Advisors LLC bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth $121,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth $259,000. Swiss National Bank grew its position in shares of Taysha Gene Therapies by 9.3% during the 1st quarter. Swiss National Bank now owns 41,000 shares of the company's stock worth $267,000 after buying an additional 3,500 shares in the last quarter. TimesSquare Capital Management LLC grew its position in shares of Taysha Gene Therapies by 1.0% during the 1st quarter. TimesSquare Capital Management LLC now owns 665,900 shares of the company's stock worth $4,342,000 after buying an additional 6,800 shares in the last quarter. Finally, Sargent Investment Group LLC bought a new position in shares of Taysha Gene Therapies during the 1st quarter worth $69,000. Hedge funds and other institutional investors own 46.05% of the company's stock.
其他幾家對衝基金和其他機構投資者最近也買賣了TSHA的股票。ProShare Advisors LLC在第四季度購買了塔莎基因療法公司的新股票，價值12.1萬美元。三菱UFJ國賽資產管理有限公司在第四季度購買了價值25.9萬美元的泰莎基因療法的新頭寸。瑞士國家銀行在第一季度持有的泰莎基因療法股票增加了9.3%。瑞士國家銀行目前持有該公司4.1萬股股票，價值26.7萬美元，上個季度又購買了3500股。TimesSquare Capital Management LLC在第一季度將其在泰莎基因療法公司的股票頭寸增加了1.0%。TimesSquare Capital Management LLC現在持有該公司66.59萬股股票，價值4,342,000美元，上個季度又購買了6,800股。最後，薩金特投資集團有限責任公司在第一季度購買了價值6.9萬美元的泰莎基因療法公司的新頭寸。對衝基金和其他機構投資者持有該公司46.05%的股份。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of equities research analysts recently weighed in on the company. Chardan Capital dropped their price objective on Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Guggenheim reduced their price objective on Taysha Gene Therapies to $22.00 and set a "na" rating for the company in a research note on Tuesday, May 17th. The Goldman Sachs Group reduced their price objective on Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th. Wedbush reduced their price objective on Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday, August 12th. Finally, Needham & Company LLC reduced their price objective on Taysha Gene Therapies to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and an average price target of $26.00.
一些股票研究分析師最近對該公司進行了分析。Chardan Capital在8月12日(星期五)的一份研究報告中將塔莎基因療法的目標價從34.00美元下調至32.00美元，並對該股設定了“買入”評級。古根海姆在5月17日星期二的一份研究報告中將塔莎基因療法的目標價格下調至22.00美元，併為該公司設定了“NA”評級。5月24日，高盛夫婦將泰莎基因療法的目標價從27美元下調至16美元，並在週二的一份研究報告中為該公司設定了買入評級。韋德布什將泰莎基因療法的目標價格從9.00美元下調至5.00美元，並在8月12日星期五的一份研究報告中為該公司設定了“跑贏大盤”的評級。最後，Needham&Company LLC在5月17日星期二的一份研究報告中將其泰莎基因療法的目標價下調至20.00美元，併為該公司設定了“買入”評級。根據MarketBeat.com的數據，11位分析師對該股的評級為買入，泰莎基因療法的平均評級為買入，平均目標價為26.00美元。
Taysha Gene Therapies Stock Down 3.6 %
泰莎基因療法公司股價下跌3.6%
Insider Transactions at Taysha Gene Therapies
泰莎基因療法公司的內幕交易
In other news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $3.53, for a total value of $84,448.19. Following the sale, the chief marketing officer now directly owns 543,450 shares of the company's stock, valued at $1,918,378.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 40,152 shares of company stock valued at $145,109 over the last ninety days. Insiders own 42.40% of the company's stock.
在其他新聞方面，CMO Suyash Prasad在7月1日星期五的一筆交易中出售了23,923股泰莎基因療法的股票。這隻股票的平均售價為3.53美元，總價值為84,448.19美元。出售後，首席營銷官現在直接持有543,450股公司股票，價值1,918,378.50美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的，可以通過這個超級鏈接訪問。在過去的90天裏，內部人士已經出售了40,152股公司股票，價值145,109美元。內部人士持有該公司42.40%的股份。
Taysha Gene Therapies Profile
泰莎基因療法簡介
(Get Rating)
(獲取評級)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
泰莎基因療法公司是一家基因治療公司，專注於開發基於腺相關病毒的基因療法並將其商業化，用於治療中樞神經系統單基因疾病。它主要開發用於治療巨大軸索性神經病的TSHA-120；用於治療Rett綜合徵的TSHA-102；用於治療CLN1疾病的TSHA-121；用於治療CLN1疾病的TSHA-118；用於治療SLC13A5缺乏症的TSHA-105；以及用於治療GM2神經節苷脂缺乏的TSHA-101。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
- 免費獲取StockNews.com關於塔莎基因療法的研究報告(TSHA)
- 2家電動汽車供應商在提出意見後上漲
- 應用材料公司業績顯示半導體市場放緩
- MarketBeat：回顧中的一週8/15-8/19
- 蘋果股價可能再次上漲30%
- 近期逆風為Ross Stores帶來機遇
Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating).
想看看其他對衝基金持有TSHA的股票嗎？訪問HoldingsChannel.com獲取泰莎基因療法公司(納斯達克代碼：TSHA-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《泰莎基因療法日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對塔莎基因療法和相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。